Atria Investments Inc Has $18.95 Million Stake in Abbott Laboratories (NYSE:ABT)

Atria Investments Inc grew its position in Abbott Laboratories (NYSE:ABT - Free Report) by 2.6% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 167,507 shares of the healthcare product maker's stock after acquiring an additional 4,289 shares during the quarter. Atria Investments Inc's holdings in Abbott Laboratories were worth $18,947,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also made changes to their positions in ABT. Groupama Asset Managment raised its holdings in shares of Abbott Laboratories by 22.2% during the third quarter. Groupama Asset Managment now owns 228,448 shares of the healthcare product maker's stock worth $26,000 after purchasing an additional 41,557 shares during the period. Noble Wealth Management PBC acquired a new stake in Abbott Laboratories during the fourth quarter worth about $26,000. NewSquare Capital LLC lifted its holdings in Abbott Laboratories by 78.4% in the fourth quarter. NewSquare Capital LLC now owns 239 shares of the healthcare product maker's stock worth $27,000 after acquiring an additional 105 shares during the last quarter. Peterson Financial Group Inc. bought a new position in shares of Abbott Laboratories during the third quarter valued at approximately $32,000. Finally, Wingate Wealth Advisors Inc. acquired a new stake in shares of Abbott Laboratories during the 4th quarter worth approximately $34,000. 75.18% of the stock is owned by institutional investors and hedge funds.

Abbott Laboratories Price Performance

Abbott Laboratories stock traded up $0.10 during midday trading on Wednesday, hitting $137.68. The company's stock had a trading volume of 8,155,906 shares, compared to its average volume of 5,485,037. Abbott Laboratories has a 12 month low of $99.71 and a 12 month high of $141.23. The company has a quick ratio of 1.14, a current ratio of 1.60 and a debt-to-equity ratio of 0.32. The company has a market capitalization of $238.79 billion, a PE ratio of 18.00, a price-to-earnings-growth ratio of 2.52 and a beta of 0.75. The stock's 50-day moving average price is $124.51 and its 200-day moving average price is $118.42.

Abbott Laboratories (NYSE:ABT - Get Free Report) last released its earnings results on Wednesday, January 22nd. The healthcare product maker reported $1.34 EPS for the quarter, hitting analysts' consensus estimates of $1.34. The business had revenue of $10.97 billion for the quarter, compared to the consensus estimate of $11.03 billion. Abbott Laboratories had a net margin of 31.95% and a return on equity of 20.74%. The business's revenue for the quarter was up 7.2% on a year-over-year basis. During the same period in the previous year, the firm earned $1.19 EPS. Analysts anticipate that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.

Abbott Laboratories Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, May 15th. Investors of record on Tuesday, April 15th will be issued a $0.59 dividend. This represents a $2.36 dividend on an annualized basis and a dividend yield of 1.71%. The ex-dividend date of this dividend is Tuesday, April 15th. Abbott Laboratories's payout ratio is 30.85%.

Insider Transactions at Abbott Laboratories

In other news, EVP Daniel Gesua Sive Salvadori sold 23,771 shares of the business's stock in a transaction that occurred on Thursday, January 30th. The shares were sold at an average price of $128.50, for a total transaction of $3,054,573.50. Following the sale, the executive vice president now owns 125,697 shares in the company, valued at $16,152,064.50. The trade was a 15.90 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Eric Shroff sold 562 shares of the company's stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $138.17, for a total transaction of $77,651.54. Following the completion of the sale, the senior vice president now owns 31,970 shares of the company's stock, valued at approximately $4,417,294.90. This trade represents a 1.73 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 25,282 shares of company stock valued at $3,263,348 over the last three months. Company insiders own 1.10% of the company's stock.

Wall Street Analyst Weigh In

ABT has been the subject of a number of analyst reports. Argus upgraded Abbott Laboratories to a "strong-buy" rating in a research report on Tuesday, January 28th. The Goldman Sachs Group boosted their price target on shares of Abbott Laboratories from $138.00 to $154.00 and gave the company a "buy" rating in a report on Tuesday. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $135.00 price objective on shares of Abbott Laboratories in a report on Tuesday, January 21st. Evercore ISI boosted their target price on shares of Abbott Laboratories to $136.00 and gave the company a "buy" rating in a research note on Thursday, January 2nd. Finally, Wells Fargo & Company raised their price target on shares of Abbott Laboratories from $133.00 to $136.00 and gave the company an "overweight" rating in a research note on Thursday, January 23rd. Four equities research analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $137.19.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.